The meaning of “protected by a basic patent” has been clarified in Teva v Gilead, in a return to familiar ground The Court of Justice of the EU today clarified when a product is protected by a basic ...
The CJEU attempted to clarify the meaning of “protected by a basic patent” in Teva v Gilead, but practitioners and in-house counsel say it raises more questions than it has answered including a new ...
The Court of Justice of the European Union (CJEU) rendered a landmark decision extending patent term extensions for certain medicinal products in litigation relating to supplementary protection ...
Forest Laboratories is suing generic-drug maker Teva Pharmaceutical Industries for infringing the basic patent on its antidepressant Lexapro, for which Forest recorded $480 million in global sales in ...
The cost for a typical US patent, from start to finish, is between $10,000 and $40,000, and generally takes 2-7 years. Currently, the published average time from filing to grant is about 3 1/2 years.
I would like to thank USPTO Director John Squires for his initiative to stop serial patent challenges at the USPTO....
NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893 basic patent for Lipitor, initially rejecting the ...
Before Prost, Newman, and Reyna. Appeal from the District Court for the District of New Jersey. Summary: Claims using “consisting essentially of” to define an open-ended list of ingredients are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback